Evidence map›Paper›PMID 32938228›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2021

Role of GATA3 exon 6 germline mutations in breast cancer progression in Egyptian female patients.

Iman H Ibrahim, Heba G Abdel-Aziz, Fatema Em Hassan, Hesham Sa El-Sameea

Open access · bronzeAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Iman H IbrahimDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy (Girls) Al-Azhar University, Cairo 11765, EgyptORCID 0000-0001-5752-2107
Heba G Abdel-AzizDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy (Girls) Al-Azhar University, Cairo 11765, Egypt
Fatema Em HassanDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy (Girls) Al-Azhar University, Cairo 11765, Egypt
Hesham Sa El-SameeaDepartment of Clinical Pathology, Faculty of Medicine (New Damietta) Al-Azhar University, Damietta 34711, Egypt.
Al-Azhar University · EGDamietta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

impact statementGATA3 mutations are known to play an important role in breast cancer progression. The exact role and mechanisms of these mutations remain controversial as some studies suggest a relation to breast tumor growth, while others suggest a relation to longer survival. GATA3 germline mutations are not well studied in breast cancer. In this study, it was hypothesized that different types of GATA3 mutations could contribute to the breast cancer progression in different ways. GATA3 exon 6, which is important for GATA3 protein functions, was reported to have hotspots, and hence it was selected for study. Intronic GATA3 germline mutations were found to be related to favorable prognosis, while protein coding mutations were found to be related to unfavorable prognosis. Bioinformatics study of large publically available datasets showed that GATA3 mutations lead to dysregulation of pathways related to T-cells activation, inflammation, and breast cancer development.

Indexed as

Disease ProgressionBreast NeoplasmsCodonDNA Mutational AnalysisEgyptExonsFemaleGATA3 Transcription FactorGene Expression Regulation, NeoplasticGerm-Line MutationHumansMiddle AgedCodonGATA3 protein, humanGATA3 Transcription Factorbioinformaticsbreast cancerDFSdriver genesGATA3mutation

Identifiers

PMID32938228
PMCPMC7797995
OpenAlexW3087307139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.